WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 522390
Description: GW627368X is a novel, potent and selective competitive antagonist of prostanoid EP4 receptors with additional human TP receptor affinity. Oral administration of GW627368X showed significant tumor regression characterized by tumor reduction and induction of apoptosis. Reduction in prostaglandin E2 synthesis also led to reduced level of VEGF in plasma. GW627368X will be a valuable tool to explore the role of the prostanoid EP4 receptor in many physiological and pathological settings.
MedKoo Cat#: 522390
Chemical Formula: C30H28N2O6S
Exact Mass: 544.16681
Molecular Weight: 544.62
Elemental Analysis: C, 66.16; H, 5.18; N, 5.14; O, 17.63; S, 5.89
GW627368X, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.
Synonym: GW627368X; GW 627368X; GW-627368X; GW627368; GW 627368; GW-627368.
IUPAC/Chemical Name: 2-(4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl)-N-(phenylsulfonyl)acetamide
InChi Key: XREWXJVMYAXCJV-UHFFFAOYSA-N
InChi Code: InChI=1S/C30H28N2O6S/c1-3-37-28-23-12-8-9-13-24(23)29(38-4-2)27-25(28)19-32(30(27)34)21-16-14-20(15-17-21)18-26(33)31-39(35,36)22-10-6-5-7-11-22/h5-17H,3-4,18-19H2,1-2H3,(H,31,33)
SMILES Code: O=C(NS(=O)(C1=CC=CC=C1)=O)CC2=CC=C(N(CC3=C4C(OCC)=C(C=CC=C5)C5=C3OCC)C4=O)C=C2
The following data is based on the product molecular weight 544.62 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Parida S, Parekh A, Dey G, Ghosh SC, Mandal M. Molecular inhibition of
prostaglandin E2 with GW627368X: Therapeutic potential and preclinical safety
assessment in mouse sarcoma model. Cancer Biol Ther. 2015;16(6):922-32. doi:
10.1080/15384047.2015.1040953. Epub 2015 Apr 20. PubMed PMID: 25894216.
2: Wilson RJ, Giblin GM, Roomans S, Rhodes SA, Cartwright KA, Shield VJ, Brown J,
Wise A, Chowdhury J, Pritchard S, Coote J, Noel LS, Kenakin T, Burns-Kurtis CL,
Morrison V, Gray DW, Giles H. GW627368X
benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor
antagonist. Br J Pharmacol. 2006 Jun;148(3):326-39. PubMed PMID: 16604093; PubMed
Central PMCID: PMC1751567.